Related Experiment Video
Updated: Apr 18, 2026

11:10
Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
Published on: December 27, 2010
12.9K
Development and genomic characterization of a diverse HIV-1 variant reference panel for nucleic acid-based testing
Jiangqin Zhao1, Tianxiong Li1, Hanxia Huang1
1Laboratory of Molecular Virology, DETTD, OBRR, CBER, FDA, 10903 New Hampshire Ave, Silver Spring, MD, United States.
Summary
A diverse HIV-1 reference panel was created to address challenges in HIV nucleic acid testing (NAT) due to global genetic diversity. This panel aids in evaluating the analytical performance of HIV NAT assays.
Area of Science:
- Virology
- Molecular Biology
- Public Health
Background:
- Global Human Immunodeficiency Virus (HIV) genetic diversity complicates accurate detection and diagnosis via nucleic acid testing (NAT).
- Well-characterized reference panels are crucial for assessing the analytical performance of HIV diagnostic tests.
Purpose of the Study:
- To develop a comprehensive reference panel for HIV NAT that accurately represents the genetic diversity of circulating HIV strains.
- To create a standardized tool for validating HIV detection methods.
Main Methods:
- HIV-1 strains were cultured from clinical specimens in Cameroon.
- Near full-length genomes were sequenced using metagenomic next-generation sequencing and Sanger sequencing.
- A diverse subset of 18 HIV-1 strains was selected to form the reference panel, with viral loads quantified at low, medium, and high levels.
Main Results:
- Near full-length HIV-1 genomes (average 9589 bp) were obtained for 37 out of 59 strains.
- The panel includes 18 diverse HIV-1 strains: 4 subtypes, 4 circulating recombinant forms, and 8 unique recombinant forms.
- Panel members were prepared at three viral load concentrations (low, medium, high), resulting in 51 total panel members.
Conclusions:
- The developed HIV reference panel effectively represents diverse circulating strains.
- This panel is a valuable resource for evaluating the performance of HIV NAT assays.
- The panel is available to developers and manufacturers of HIV diagnostic tests upon request.

